Venetoclax + obinutuzumab
Venetoclax + obinutuzumab has been studied in 1 paper since 2023: 1 trial in people. The newest paper, Jun 26, 2023: “Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL”.
1 paper studies it2 findingsUpdated
“During treatment, the number of geriatric impairments diminished significantly”
None of its findings points the other way.
- 1 lab
- Human trial1
Studies in people
1 study gave venetoclax + obinutuzumab to people and measured what changed.
down: Decreases geriatric impairments
up: Improves health-related quality of life
Trial67 people12 cycles
Older adults; FCR-unfit patients with CLL
Blood, Jun 26, 2023
What did studies of Venetoclax + obinutuzumab find?
2Studies of Venetoclax + obinutuzumab measured 2 outcomes; the most studied are health-related quality of life (1 study) and geriatric impairments (1).
Health-related quality of life
upin humans1
1 study
Health-related quality of life
upin humans1
Venetoclax + obinutuzumab improves health-related quality of life in humans.
“clinically relevant improvements in HRQoL subscales were reached for global health status, physical functioning, role functioning, emotional functioning, fatigue, dyspnea, physical condition or fatigue, and worries or fears related to health and functioning.”
Human trialFCR-unfit patients with CLLn = 67
Blood
Geriatric impairments
downin humans1
1 study
Geriatric impairments
downin humans1
Venetoclax + obinutuzumab decreases geriatric impairments in humans.
“During treatment, the number of geriatric impairments diminished significantly”
Human trialFCR-unfit patients with CLLn = 67
Blood